AUG 18, 2026 · PHASE 3 TRIAL
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
ClinicalTrials.gov
This is a Phase 3 trial registration with no reported results; the study is active but not recruiting, so outcomes remain unreported in this registry record.
Reported
Planned enrollment160
Study phasePhase 3
Primary outcome measureResidual Cancer Burden 0/1 rate as assessed…